GoodRx (NASDAQ:GDRX) Sets New 1-Year Low – Here’s What Happened

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $2.24 and last traded at $2.30, with a volume of 241870 shares. The stock had previously closed at $2.27.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GDRX. Mizuho reduced their price objective on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Barclays started coverage on GoodRx in a research report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Finally, Citigroup lowered their price target on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Friday, January 9th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $4.73.

GoodRx Stock Performance

The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock’s fifty day moving average is $2.71 and its two-hundred day moving average is $3.57. The firm has a market capitalization of $775.60 million, a price-to-earnings ratio of 25.39, a P/E/G ratio of 0.86 and a beta of 1.50.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business’s revenue was up .4% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. On average, analysts predict that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Institutional Trading of GoodRx

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after acquiring an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. boosted its position in GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after purchasing an additional 184,734 shares during the period. LSV Asset Management increased its holdings in shares of GoodRx by 517.1% in the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock valued at $9,960,000 after purchasing an additional 1,973,017 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of GoodRx by 16.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after purchasing an additional 236,896 shares during the period. Finally, Pathway Capital Management LP lifted its stake in shares of GoodRx by 69.0% during the 3rd quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock worth $4,171,000 after buying an additional 402,721 shares during the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.